- Home
- HPK vs DRTS Comparison
HPK vs DRTS Comparison
Compare HPK & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | DRTS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | Israel |
| Employees | 47 | 125 |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.1M | 546.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HPK | DRTS |
|---|---|---|
| Price | $6.57 | $7.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $11.00 | $8.67 |
| AVG Volume (30 Days) | ★ 1.2M | 278.2K |
| Earning Date | 03-11-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.57 |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $2.30 |
| 52 Week High | $13.06 | $8.60 |
Technical Indicators
Market Signals| Indicator | HPK | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 50.84 |
| Support Level | $5.10 | $6.37 |
| Resistance Level | $7.33 | $7.75 |
| Average True Range (ATR) | 0.52 | 0.41 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 72.56 | 64.16 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.